Online citations, reference lists, and bibliographies.
← Back to Search

Formulation Of PPAR-gamma Agonist As Surface Modified PLGA Nanoparticles For Non-invasive Treatment Of Diabetic Retinopathy: In Vitro And In Vivo Evidences

Umesh D. Laddha, S. Kshirsagar
Published 2020 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Diabetic retinopathy is one of the worst complications of diabetes and it is treated by invasive method. We prepared a surface modified poly (D, L-lactide-co-glycolide) i.e. PLGA nanoparticles for delivery of pioglitazone-a peroxisome proliferator-activated receptor-gamma agonist to posterior segment of the eye by topical administration. The present study investigated two grades of PLGA viz. 75:25 and 50:50. Surface modification was performed using polysorbate 80. Nanoparticles were prepared by single emulsion solvent evaporation method and optimized by using 3-factor 3-level Box-Behnken statistical design. Mean particle size, PDI and entrapment efficiency for optimized batch of PLGA 75:25 was found to be 163.23 nm, 0.286 and 91%, whereas; for PLGA 50:50 it was 171.7 nm, 0.280 and 93% respectively. DSC confirms the molecular dispersion of drug in polymer. In vitro release study showed biphasic drug release pattern with 58.48 ± 1.38% and 74.17 ± 1.38% cumulative drug release by PLGA 75:25 and 50:50 nanoparticles at the end of 10h. The release profile of pioglitazone from nanoparticles appeared to fit best with Higuchi model. In vivo study on rat showed dose dependent reduction in vascular endothelial growth factor concentration in vitreous fluid. The study reveals significance of peroxisome proliferator-activated receptor-gamma in management of diabetic retinopathy.
This paper references
10.4103/0301-4738.40355
Diabetic retinopathy: An update
R. Singh (2008)
10.1111/dom.12384
New treatments for diabetic retinopathy
A. Das (2015)
10.1515/9783050077338-026
Y
E. M. S. J. xviii (1824)
10.3109/02652048.2011.576785
Paclitaxel-loaded polyester nanoparticles prepared by spray-drying technology: in vitro bioactivity evaluation
P. López-Gasco (2011)
10.1080/03639040600975147
Preparation of Azithromycin Nanosuspensions by High Pressure Homogenization and its Physicochemical Characteristics Studies
Dianrui Zhang (2007)
Molecular Implication of the PPARs in Diabetic Eye
A. Ciudin (2013)
10.1208/s12249-015-0448-0
A Novel Method for Preparing Surface-Modified Fluocinolone Acetonide Loaded PLGA Nanoparticles for Ocular Use: In Vitro and In Vivo Evaluations
A. Salama (2015)
The VEGF paradox: dose diabetic retinopathy protect from age related macular degeneration? Med
M. Saravia (2017)
10.1155/2012/629452
Therapeutic Interventions against Inflammatory and Angiogenic Mediators in Proliferative Diabetic Retinopathy
D. Gologorsky (2012)
10.1248/CPB.57.657
Particle characterization of poorly water-soluble drugs using a spray freeze drying technique.
M. Kondo (2009)
The VEGF paradox : dose diabetic retinopathy protect from age related macular degeneration ?
E. M. Kohner
10.1080/21691401.2016.1243545
Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation
J. Pandit (2017)
10.3390/pharmaceutics10020057
Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems
M. Danaei (2018)
FABRICATION OF BIODEGRADABLE POLY(D,L-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES CONTAINING TAMOXIFEN CITRATE
F. Mirzajani (2010)
10.1016/j.mehy.2017.10.001
The VEGF paradox: Does diabetic retinopathy protect from age related macular degeneration?
M. Saravia (2017)
Clarke
J. Kusari (2010)
Vectrichelvan, Formulation, characterization and optimization of pioglitazone hydrochloride nanoparticles by solvent displacement method using 3 2 factorial design
A U Faruksha (2013)
10.1111/j.1476-5381.2011.01411.x
Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR‐γ‐related pharmacology
M. K. Song (2012)
10.1016/j.ajps.2017.03.002
Feasibility of drug delivery to the eye's posterior segment by topical instillation of PLGA nanoparticles
Kohei Tahara (2017)
10.1167/iovs.08-3293
Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine.
Jyotirmoy Kusari (2010)
10.1016/j.sjopt.2011.01.009
Diabetic retinopathy - An update.
A. Alghadyan (2011)
10.1080/21691401.2016.1203794
PLGA nanoparticles for ocular delivery of loteprednol etabonate: a corneal penetration study
A. K. Sah (2017)
10.2307/j.ctvrnfqk1.10
? ? ? ? f ? ? ? ? ?
A. ADoefaa (2003)
10.1016/j.ejpb.2010.03.013
Cellular uptake mechanisms and intracellular distributions of polysorbate 80-modified poly (D,L-lactide-co-glycolide) nanospheres for gene delivery.
K. Tahara (2010)
10.1155/2013/343560
Pathophysiology of Diabetic Retinopathy
J. Tarr (2013)
10.1155/2014/683153
Cyclosporine A Loaded PLGA Nanoparticles for Dry Eye Disease: In Vitro Characterization Studies
Vijay D. Wagh (2014)
Retinopathy Treatment
K. Boyd (2020)
10.1155/2013/106594
Animal Models of Diabetic Retinopathy: Summary and Comparison
A. Lai (2013)
10.1080/13602360500115095
Formulation
J. Peponis (2005)
Figure 7. Effect of formulation on VEGF in rats
10.1186/1743-7075-11-8
Beneficial effects of the nutritional supplements on the development of diabetic retinopathy
R. Kowluru (2014)
10.4172/2155-983X.1000129
Effect of Polymer and Formulation Variables on Properties of Self-Assembled Polymeric Micellar Nanoparticles
D. Bhambere (2014)
10.1016/j.colsurfb.2016.02.026
Carboplatin loaded Surface modified PLGA nanoparticles: Optimization, characterization, and in vivo brain targeting studies.
S. Jose (2016)
Published by American Academy of ophthalmology
K Boyd
10.3109/10717544.2014.987333
Preparation and evaluation of nanoparticles loaded ophthalmic in situ gel
Rajesh Kesarla (2016)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar